A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

March 23, 2010

Primary Completion Date

July 27, 2011

Study Completion Date

July 27, 2011

Conditions
Psoriasis
Interventions
DRUG

peficitinib

oral

DRUG

Placebo

oral

Trial Locations (11)

23507

Virginia Clinical Research, Norfolk

29607

Palmetto Clinical Trial Services, Greenville

33175

FXM Research, Corp., Miami

34471

Renstar Medical Research, Ocala

35205

Total Skin & Beauty Dermatology Center, Birmingham

37072

Rivergate Dermatology, Goodlettsville

40217

Derm Research, PLLC, Louisville

53719

Madison Skin & Research, Inc, Madison

77845

J & S Studies, College Station

92123

Therapeutics Clinical Research, San Diego

97223

Oregon Medical Research Center, Portland

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT01096862 - A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis | Biotech Hunter | Biotech Hunter